Curie Element: Experience of Radium-223 Use in Patients With Bone Metastases in Castration-Resistant Prostate Cancer

Introduction. Radionuclide therapy of bone metastases with radium-223 dichloride has been approved for patients with castration-resistant prostate cancer. Targeted therapy, which is being actively introduced into clinical practice, can im‑ prove overall survival rates, reduce pain with the possibility of discontinuing potent analgesic drugs, and reduce or delay the risk of potentially serious complications, such as pathological fractures and spinal cord compression. Objective. To evaluate the effectiveness of radium-223 dichloride in patients with castration-resistant prostate cancer. Materials and methods. Since 2023, at the Clinic of the Bashkir State Medical University, 43 patients with metastatic castrationresistant prostate cancer have received radionuclide therapy. Prior to each administration of radium-223 dichloride, blood parameters and prostate-specific antigen were monitored; functional status and pain syndrome were assessed. Patients were divided into groups depending on the use of radium-223 dichloride as a second-, third-, or fourth-line therapy. The drug effectiveness was assessed using control bone scintigraphy. Results and discussion. 62.7% of the pa‑ tients who completed the course of radionuclide therapy showed stabilization of the process, which is consistent with the data of key publications of the largest world databases. Overall survival was higher in the group receiving the drug as a second-line therapy compared to that in the groups of later lines. During treatment, pain syndrome decreased in 58% of patients. In the general group, the alkaline phosphatase level decreased by 16.4%, which is consistent with the data of the ALSYMPCA phase 3 randomized study. Conclusion. Our study has confirmed the clinical effectiveness of radium-223 dichloride, thereby contributing to the evidence base for the optimization of its application in routine oncological prac‑ tice. Since radium-223 dichloride is contraindicated in visceral metastases and is recommended as a second-line therapy, continuity in the work of specialists and timely routing of patients for early appointment are of high importance.

1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R. L., Soerjomataram I., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. DOI: 10.3322/caac.21834

2. Filho A.M., Laversanne M., Ferlay J., Colombet M., Piñeros M., Znaor A., et al. The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 2025;156(7):1336–46. DOI: 10.1002/ijc.35278

3. Kaprin A.D., Alekseev B.I., Matveev V.B., Pushkar’ D.I., Govorov A.V., Gorban’ N.A., et al. Prostate cancer. Journal of Modern Oncology. 2021;23(2):211–47 (In Russ.). DOI: 10.26442/18151434.2021.2.200959

4. National cancer register of the Russian Federation. Prostate Cancer Statistics 2023. [cited 2024 July 10]. Available from: https://oncologyregistry.ru

5. James N.D., Tannock I., N’Dow J., Feng F., Gillessen S., Ali S.A., et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683–722. DOI: 10.1016/S0140-6736(24)00651-2

6. Satcher R.L., Zhang X.H. Evolving cancer-niche interactions and therapeutic targets during bone metastasis. Nat Rev Cancer. 2022;22(2):85– 101. DOI: 10.1038/s41568-021-00406-5

7. Pushkar D.Yu., Kaprin A.D., Vazhenin A.V., Alelseev B.Ya., Govorov A.B., Vasilyev A.O. Treatment of common types of prostate cancer. Methodological recommendations No. 26. Мoscow: ABV-press; 2020 (In Russ.).

8. de Bono J., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., et al. Olaparib for metastatic castration-resistant prostate cancer. New Engl J Med. 2020;382(22):2091–102. DOI: 10.1056/NEJMoa1911440

9. Saad F., Thiery-Vuillemin A., Wiechno P., Alekseev B., Sala N., Jones R., et al. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2022;23(10):1297–307. DOI: 10.1016/S1470-2045(22)00498-3

10. Guo X., Li S. Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review). Oncol Rep. 2025;53(4):46. DOI: 10.3892/or.2025.8879

11. Song H., Sgouros G. Alpha and beta radiation for theragnostics. PET Clin. 2024;19(3):307–23. DOI: 10.1016/j.cpet.2024.03.006

12. LeVee A., Lin C.Y., Posadas E., Figlin R., Bhowmick N.A., Di Vizio D., et al. Clinical utility of olaparib in the treatment of metastatic castration-resistant prostate cancer: a review of current evidence and patient selection. Onco Targets Ther. 2021;14:4819–32. DOI: 10.2147/OTT.S315170

13. O’Sullivan J.M., Carles J., Cathomas R., Gomez-Iturriaga A., Heinrich D., Kramer G., et al. Radium-223 within the evolving treatment options for metastatic castration-resistant prostate cancer: recommendations from a European expert working group. Eur Urol Oncol. 2020;3(4):455–63. DOI: 10.1016/j.euo.2019.02.007

14. Sartor O., de Bono J., Chi K.N., Fizazi K., Herrmann K., Rahbar K., et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. New Engl J Med. 2021;385(12):1091–103. DOI: 10.1056/NEJMoa2107322

15. Hofman M.S., Emmett L., Sandhu S., Iravani A., Joshua A.M., Goh J.C., et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804. DOI: 10.1016/S0140-6736(21)00237-3

16. Iagaru A.H., Mittra E., Colletti P.M., Jadvar H. Bone-targeted imaging and radionuclide therapy in prostate cancer. J Nucl Med. 2016;57(Suppl 3):19S–24S. DOI: 10.2967/jnumed.115.170746

17. Nosov D.A., Volkova M.I., Gladkova O.A., Karabina E.V., Krylov V.V., Matveev V.B., et al. Practice guidelines for management of prostate cancer. Malignant tumors. 2022;12(3s2):607–26 (In Russ.). DOI: 10.18027/2224-5057-2022-12-3s2-607-626

18. Parker C., Finkelstein S.E., Michalski J.M., O’Sullivan J.M., Bruland O, Vogelzang N.J., et al. Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA Trial. Eur Urol. 2016;70(5):875–83. DOI: 10.1016/j.eururo.2016.06.002

19. Vyazmin V.V., Shumilina N.YU., Zukov R.A. Optimization of selection criteria and evaluation of radium-223 therapy effectiveness in patients with prostate cancer. Effective Pharmacotherapy. 2021;17(2):22–8 (In Russ.). DOI: 10.33978/2307-3586-2021-17-2-22-28

20. Taich L., Zhao H., Stock S. R., Howard L. E., De Hoedt A. M., Terris M. K., et al. Radium-223 utilization patterns and outcomes in clinical practice. Urol Pract. 2022;9(5):405–13. DOI: 10.1097/UPJ.0000000000000316

21. George D.J., Agarwal N., Sartor O., Sternberg C.N., Tombal B., Saad F., et al. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castrationresistant prostate cancer (EPIX study). Prostate Cancer Prostatic Dis. 2022;25(2):306–13. DOI: 10.1038/s41391-021-00488-0

22. Chiang P., Chiang P., Chen I.A., Chen Y.T., Wang H.J., Cheng Y.T., et al. Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan. Medicine. 2023;102(5):e32671. DOI: 10.1097/MD.0000000000032671

23. Romero-Laorden N., Lorente D., de Velasco G., Lozano R., Herrera B., Puente J., et al. Prospective assessment of bone metabolism biomarkers and survival in metastatic castration-resistant prostate cancer patients treated with radium-223: The PRORADIUM study. Eur Urol Oncol. 2024;7(3):447–55. DOI: 10.1016/j.euo.2023.09.015

24. Miyoshi Y., Tsutsumi S., Yasui M., Kawahara T., Uemura K. I., Hayashi N., et al. A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer. World J Urol. 2021;39(9):3323–8. DOI: 10.1007/s00345-021-03639-z

25. Matsumoto T., Hori Y., Shiota M., Blas L., Nakamura M., Seki N., et al. Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study. Int J Urol. 2023;30(2):139–46. DOI: 10.1111/iju.15078

26. Stattin P., Westerberg M., Lissbrant I.F., Eriksson M.H., Kjellman A., Ullén A., et al. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2023;21(1):107. e1–e9. DOI: 10.1016/j.clgc.2022.09.002

27. Hameed M.Y., Gul M., Chaudhry A., Muzaffar H., Sheikh M., Chee W., et al. From oncogenesis to theranostics: the transformative role of PSMA in prostate cancer. Cancers. 2024;16(17):3039. DOI: 10.3390/cancers16173039

28. Ahdi H.S., Wichelmann T.A., Pandravada S., Ehrenpreis E.D. Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS). BMC Pharmacol. Toxicol. 2023;24(1):15. DOI: 10.1186/s40360-023-00657-y

29. Trieu J., Chang M., Rojas V., Varada N., Cao Y., Anderson M., et al. Lower fracture rates in patients treated with radium-223, abiraterone or enzalutamide, when given concurrently with bone health agents: a real-world analysis. Clin Genitourin Cancer. 2022;20(5):399–403. DOI: 10.1016/j.clgc.2022.04.015

30. McDermott R.S., Greene J., McCaffrey J., Parker I., Helanova S., Baird A.M., et al. Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study. Ther Adv Med Oncol. 2021;13:17588359211042691. DOI: 10.1177/17588359211042691

31. Reis G., Dos Santos Moreira-Silva E.A., Silva D.C.M., Thabane L., Milagres A.C., Ferreira T.S., et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10(1):e42–51. DOI: 10.1016/S2214-109X(21)00448-4